AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
Objective: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the functio...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Royan Institute (ACECR), Tehran
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d0a174c47a674058bb15b47c9426b3fd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sea el primero en dejar un comentario!